Blue Cross NC policies

Search Blue Cross NC's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

Checking prior authorization for 81405? Open Blue Cross NC’s official lists and confirm the member’s product there.

53 policies name 81405, those listing the fewest codes first. A policy that names a code may also list it as excluded.

Blue Cross NC policies
PolicyDetailsCodesSource
Genetic Testing for Germline Mutations RET Proto-Oncogene Medullary Carcinoma Thyroid AHS-M2078AHS-M2078 · Commercial2Original policy ↗
Genetic Testing for Epilepsy AHS – M2075M2075 · Commercial4Original policy ↗
Genetic Testing for Germline Variants of the RET Proto-Oncogene AHS - M2078M2078 · Commercial4Original policy ↗
Marfan Syndrome AHS – M2144M2144 · Commercial4Original policy ↗
Genetic Testing for CHARGE Syndrome AHS - M2070M2070 · Commercial5Original policy ↗
Genetic Testing for Familial Hypercholesterolemia AHS – M2137M2137 · Commercial5Original policy ↗
Genetic Testing for Li-Fraumeni Syndrome AHS – M2081M2081 · Commercial5Original policy ↗
Genetic Testing for Macular Degeneration AHS-M2083AHS-M2083 · Commercial5Original policy ↗
Mutation Testing for Limb-Girdle Muscular Dystrophies AHS – M2128M2128 · Commercial5Original policy ↗
Genetic Testing for Familial Hypercholesterolemia AHS – M2137M2137 · Commercial6Original policy ↗
Genetic Testing for Rett Syndrome AHS – M2088M2088 · Commercial6Original policy ↗
Genetic Testing for Connective Tissue Disorders AHS - M2144M2144 · Commercial7Original policy ↗
Genetic Testing for Familial Alzheimer’s Disease AHS – M2038M2038 · Commercial7Original policy ↗
Genetic Testing for Familial Alzheimer’s Disease AHS – M2038M2038 · Commercial7Original policy ↗
Genetic Testing for Hereditary Pancreatitis AHS – M2079M2079 · Commercial7Original policy ↗
Genetic Testing for Hereditary Pancreatitis AHS – M2079M2079 · Commercial7Original policy ↗
Genetic Testing for Rett Syndrome AHS – M2088M2088 · Commercial7Original policy ↗
Genetic Testing for Diagnosis of Inherited Peripheral Neuropathies AHS – M2072M2072 · Commercial8Original policy ↗
Genetic Testing for Familial Alzheimer’s DiseaseAHS – M2038 · Commercial8Original policy ↗
Genetic Testing for Polyposis Syndromes AHS-M2024AHS-M2024 · Commercial9Original policy ↗
Genetic Testing for Diagnosis of Inherited Peripheral Neuropathies AHS – M2072M2072 · Commercial10Original policy ↗
Genetic Testing for Epilepsy AHS – M2075M2075 · Commercial10Original policy ↗
Genetic Testing for Epilepsy AHS – M2075M2075 · Commercial10Original policy ↗
Genetic Testing for Epilepsy AHS – M2075 NotificationM2075 · Commercial10Original policy ↗
Genetic Testing for Ophthalmologic Conditions AHS-M2083AHS-M2083 · Commercial13Original policy ↗
Testing for Colorectal Cancer Management AHS - M2026M2026 · Commercial13Original policy ↗
Genetic Markers for Assessing Risk of Cardiovascular Disease AHS - M2180M2180 · Commercial14Original policy ↗
Genetic Testing for Cardiac Ion Channelopathies AHS – 2025Commercial14Original policy ↗
Genetic Testing for Acute Myeloid Leukemia AHS-M2062AHS-M2062 · Commercial15Original policy ↗
Genetic Testing for Muscular Dystrophies AHS – M2074M2074 · Commercial15Original policy ↗
Genetic Testing for Inherited Cardiomyopathies and Channelopathies AHS – M2025M2025 · Commercial17Original policy ↗
Genetic Testing for Neurofibromatosis and Related Disorders AHS – M2134M2134 · Commercial19Original policy ↗
Genetic Testing of Mitochondrial Disorders AHS – M2085M2085 · Commercial22Original policy ↗
Pharmacogenetics Testing AHS – M2021M2021 · Commercial22Original policy ↗
Testing for Targeted Therapy of Non-Small-Cell Lung Cancer AHS - M2030 "Notification"M2030 · Commercial27Original policy ↗
Testing for Targeted Therapy of Non-Small-Cell Lung Cancer AHS - M2030M2030 · Commercial28Original policy ↗
Genomic Testing for Hematopoietic Neoplasms AHS- M2182AHS-M2182 · Commercial29Original policy ↗
Esophageal Pathology Testing AHS – M2171M2171 · Commercial32Original policy ↗
Esophageal Pathology Testing AHS - M2171M2171 · Commercial34Original policy ↗
Mutation Analysis in Myeloproliferative Neoplasms AHS - M2101M2101 · Commercial35Original policy ↗
General Genetic Testing, Somatic Disorders AHS-M2146AHS-M2146 · Commercial54Original policy ↗
Prenatal Screening (Genetic) AHS – M2179M2179 · Commercial54Original policy ↗
Genetic Testing for Neurodegenerative Disorders AHS – M2167M2167 · Commercial60Original policy ↗
Genomic Testing for Hematopoietic Neoplasms AHS- M2182AHS- M2182 · Commercial62Original policy ↗
Prenatal Screening (Genetic) AHS - M2179M2179 · Commercial67Original policy ↗
Prenatal Screening (Genetic) AHS - M2179 NotificationM2179 · Commercial67Original policy ↗
General Genetic Testing, Germline Disorders AHS – M2145M2145 · Commercial77Original policy ↗
Pharmacogenetics Testing AHS - M2021M2021 · Commercial89Original policy ↗
General Genetic Testing, Somatic Disorders AHS - M2146AHS-M2146 · Commercial92Original policy ↗
Liquid Biopsy AHS - G2054 NotificationG2054 · Commercial92Original policy ↗

Back to Blue Cross NC · Blue Cross NC prior authorization CPT list

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.